» Articles » PMID: 8883142

Normal and Leukemic Human Stem Cells Assayed in SCID Mice

Overview
Journal Semin Immunol
Date 1996 Aug 1
PMID 8883142
Citations 30
Authors
Affiliations
Soon will be listed here.
Abstract

Understanding the processes that regulate the developmental program of normal stem cells and those that initiate proliferative diseases such as leukemia remains one of the major challenges in biology. Progress to address these major questions in the human hematopoietic system have been hampered, until recently, by the lack of in-vivo assays for normal and leukemic stem cells. The recent development of methods to transplant normal and leukemic human hematopoietic cells into immune-deficient mice provides an important approach to identify, characterize and purify stem cells. This review will focus on the development of assays for normal and leukemic human stem cells and on the new insights these assays are beginning to provide on the organization of the human stem cell hierarchy and mechanisms of leukemogenesis.

Citing Articles

How can we establish animal models of HIV-associated lymphoma?.

Xiao Q, Zhai L, Zhang X, Liu Y, Li J, Xie X Animal Model Exp Med. 2024; 7(4):484-496.

PMID: 38567763 PMC: 11369037. DOI: 10.1002/ame2.12409.


Challenges in Cell Fate Acquisition to Scid-Repopulating Activity from Hemogenic Endothelium of hiPSCs Derived from AML Patients Using Forced Transcription Factor Expression.

Porras D, Reid J, Tanasijevic B, Golubeva D, Boyd A, Bhatia M Cells. 2022; 11(12).

PMID: 35741044 PMC: 9221973. DOI: 10.3390/cells11121915.


Cancer stem cells in breast and prostate: Fact or fiction?.

Sampayo R, Bissell M Adv Cancer Res. 2019; 144:315-341.

PMID: 31349902 PMC: 7314432. DOI: 10.1016/bs.acr.2019.03.010.


One-Year Observation of the SCID-Repopulating Cell Activities of Human Cord Blood-Derived CD34-Positive and -Negative Hematopoietic Stem Cells.

Matsuoka Y, Sumide K, Sonoda Y Stem Cell Rev Rep. 2019; 15(3):459-461.

PMID: 30982173 DOI: 10.1007/s12015-019-09884-5.


CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.

Jiang Y, Liu B, Zheng Q, Panuganti S, Chen R, Zhu J Blood Adv. 2018; 2(14):1738-1749.

PMID: 30037800 PMC: 6058235. DOI: 10.1182/bloodadvances.2018020107.